US equities |
META $626.93 ▼-0.58% TSLA $402.53 ▲+2.79% MU $925.82 ▲+2.45% NVDA $217.68 ▲+0.78% SPCX $149.57 ▲+1.82% AMD $553.63 ▲+4.21% SNDK $1,299.78 ▲+3.52% INTC $92.95 ▲+2.74%
FinancialContent

Schrodinger, Inc. - Common Stock (NQ:SDGR)

26.41 +1.91 (+7.82%)
Delayed Quote Updated: 11:06 AM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
From Schrödinger
Via Business Wire
News headline image
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details ↗
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Schrödinger Reports Third Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
News headline image
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Present at Jefferies London Healthcare Conference
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
From Schrödinger
Via Business Wire
News headline image
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
News headline image
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
From Schrödinger
Via Business Wire
News headline image
The 3 Best Med Tech Stocks to Buy Now ↗
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
News headline image
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024 ↗
SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Schrödinger Reports Strong Second Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
News headline image
3 Small-Cap Stocks to Buy at a 52-Week Low ↗
The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
Via InvestorPlace
News headline image
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
From Schrödinger
Via Business Wire
News headline image
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts ↗
The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts. 
Via InvestorPlace
Topics Economy
News headline image
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
News headline image
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >